Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients

Tsu Yi Chao, Jyh Cherng Yu, Chih Hung Ku, Mary M. Chen, Su Huei Lee, Anthony J. Janckila, Lung T. Yam

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Purpose: Previous studies showed that serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity was increased in 70% to 94% of breast cancer (BC) patients with bone metastasis (BM). This study aims to determine whether serum TRACP5b is useful for identifying limited or extensive BM in BC patients. Experimental Design: Serum TRACP5b activity was measured in 168 BC patients, including 81 who were newly diagnosed with early BC, 20 with extraosseous metastasis, 24 with limited BM, and 43 with extensive BM. Serum TRACP5b activity was also measured monthly in 151 patients with early BC until they developed BM. Four hundred and twenty-seven (427) healthy women ages 18 to 90 served as control. One-way ANOVA was used to compare serum TRACP5b among groups. The sensitivity and specificity of serum TRACP5b as a marker for BM were estimated by receiver operator characteristic (ROC) curves. Results: Serum TRACP5b increased with age in healthy women (P <0.0001). It was significantly elevated in patients with extensive BM compared with all other groups (P <0.0001). ROC analysis established a cutoff value of 4.026 units/L to identify patients with extensive BM with a specificity of 98% and a sensitivity of 93% (area under the curve = 0.9807; 95% CI = 0.9698-0.9915). Among the 151 patients with early BC, 6 developed limited BM and 2 developed extensive BM during the follow-up period. Serum TRACP5b remained below the cutoff value in patients with limited BM, but became significantly increased in those whose BM became extensive. Conclusion: Serum TRACP5b activity is a useful diagnostic marker for extensive BM in patients with BC.

Original languageEnglish
Pages (from-to)544-550
Number of pages7
JournalClinical Cancer Research
Volume11
Issue number2 I
Publication statusPublished - Jan 15 2005
Externally publishedYes

Fingerprint

Biomarkers
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Serum
Tartrate-Resistant Acid Phosphatase
Area Under Curve
Analysis of Variance
Research Design
Sensitivity and Specificity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chao, T. Y., Yu, J. C., Ku, C. H., Chen, M. M., Lee, S. H., Janckila, A. J., & Yam, L. T. (2005). Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients. Clinical Cancer Research, 11(2 I), 544-550.

Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients. / Chao, Tsu Yi; Yu, Jyh Cherng; Ku, Chih Hung; Chen, Mary M.; Lee, Su Huei; Janckila, Anthony J.; Yam, Lung T.

In: Clinical Cancer Research, Vol. 11, No. 2 I, 15.01.2005, p. 544-550.

Research output: Contribution to journalArticle

Chao, TY, Yu, JC, Ku, CH, Chen, MM, Lee, SH, Janckila, AJ & Yam, LT 2005, 'Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients', Clinical Cancer Research, vol. 11, no. 2 I, pp. 544-550.
Chao, Tsu Yi ; Yu, Jyh Cherng ; Ku, Chih Hung ; Chen, Mary M. ; Lee, Su Huei ; Janckila, Anthony J. ; Yam, Lung T. / Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 2 I. pp. 544-550.
@article{fcc686cc066f4c66afed1c6a7891c298,
title = "Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients",
abstract = "Purpose: Previous studies showed that serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity was increased in 70{\%} to 94{\%} of breast cancer (BC) patients with bone metastasis (BM). This study aims to determine whether serum TRACP5b is useful for identifying limited or extensive BM in BC patients. Experimental Design: Serum TRACP5b activity was measured in 168 BC patients, including 81 who were newly diagnosed with early BC, 20 with extraosseous metastasis, 24 with limited BM, and 43 with extensive BM. Serum TRACP5b activity was also measured monthly in 151 patients with early BC until they developed BM. Four hundred and twenty-seven (427) healthy women ages 18 to 90 served as control. One-way ANOVA was used to compare serum TRACP5b among groups. The sensitivity and specificity of serum TRACP5b as a marker for BM were estimated by receiver operator characteristic (ROC) curves. Results: Serum TRACP5b increased with age in healthy women (P <0.0001). It was significantly elevated in patients with extensive BM compared with all other groups (P <0.0001). ROC analysis established a cutoff value of 4.026 units/L to identify patients with extensive BM with a specificity of 98{\%} and a sensitivity of 93{\%} (area under the curve = 0.9807; 95{\%} CI = 0.9698-0.9915). Among the 151 patients with early BC, 6 developed limited BM and 2 developed extensive BM during the follow-up period. Serum TRACP5b remained below the cutoff value in patients with limited BM, but became significantly increased in those whose BM became extensive. Conclusion: Serum TRACP5b activity is a useful diagnostic marker for extensive BM in patients with BC.",
author = "Chao, {Tsu Yi} and Yu, {Jyh Cherng} and Ku, {Chih Hung} and Chen, {Mary M.} and Lee, {Su Huei} and Janckila, {Anthony J.} and Yam, {Lung T.}",
year = "2005",
month = "1",
day = "15",
language = "English",
volume = "11",
pages = "544--550",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2 I",

}

TY - JOUR

T1 - Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients

AU - Chao, Tsu Yi

AU - Yu, Jyh Cherng

AU - Ku, Chih Hung

AU - Chen, Mary M.

AU - Lee, Su Huei

AU - Janckila, Anthony J.

AU - Yam, Lung T.

PY - 2005/1/15

Y1 - 2005/1/15

N2 - Purpose: Previous studies showed that serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity was increased in 70% to 94% of breast cancer (BC) patients with bone metastasis (BM). This study aims to determine whether serum TRACP5b is useful for identifying limited or extensive BM in BC patients. Experimental Design: Serum TRACP5b activity was measured in 168 BC patients, including 81 who were newly diagnosed with early BC, 20 with extraosseous metastasis, 24 with limited BM, and 43 with extensive BM. Serum TRACP5b activity was also measured monthly in 151 patients with early BC until they developed BM. Four hundred and twenty-seven (427) healthy women ages 18 to 90 served as control. One-way ANOVA was used to compare serum TRACP5b among groups. The sensitivity and specificity of serum TRACP5b as a marker for BM were estimated by receiver operator characteristic (ROC) curves. Results: Serum TRACP5b increased with age in healthy women (P <0.0001). It was significantly elevated in patients with extensive BM compared with all other groups (P <0.0001). ROC analysis established a cutoff value of 4.026 units/L to identify patients with extensive BM with a specificity of 98% and a sensitivity of 93% (area under the curve = 0.9807; 95% CI = 0.9698-0.9915). Among the 151 patients with early BC, 6 developed limited BM and 2 developed extensive BM during the follow-up period. Serum TRACP5b remained below the cutoff value in patients with limited BM, but became significantly increased in those whose BM became extensive. Conclusion: Serum TRACP5b activity is a useful diagnostic marker for extensive BM in patients with BC.

AB - Purpose: Previous studies showed that serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity was increased in 70% to 94% of breast cancer (BC) patients with bone metastasis (BM). This study aims to determine whether serum TRACP5b is useful for identifying limited or extensive BM in BC patients. Experimental Design: Serum TRACP5b activity was measured in 168 BC patients, including 81 who were newly diagnosed with early BC, 20 with extraosseous metastasis, 24 with limited BM, and 43 with extensive BM. Serum TRACP5b activity was also measured monthly in 151 patients with early BC until they developed BM. Four hundred and twenty-seven (427) healthy women ages 18 to 90 served as control. One-way ANOVA was used to compare serum TRACP5b among groups. The sensitivity and specificity of serum TRACP5b as a marker for BM were estimated by receiver operator characteristic (ROC) curves. Results: Serum TRACP5b increased with age in healthy women (P <0.0001). It was significantly elevated in patients with extensive BM compared with all other groups (P <0.0001). ROC analysis established a cutoff value of 4.026 units/L to identify patients with extensive BM with a specificity of 98% and a sensitivity of 93% (area under the curve = 0.9807; 95% CI = 0.9698-0.9915). Among the 151 patients with early BC, 6 developed limited BM and 2 developed extensive BM during the follow-up period. Serum TRACP5b remained below the cutoff value in patients with limited BM, but became significantly increased in those whose BM became extensive. Conclusion: Serum TRACP5b activity is a useful diagnostic marker for extensive BM in patients with BC.

UR - http://www.scopus.com/inward/record.url?scp=12244276359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244276359&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 544

EP - 550

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2 I

ER -